2nd NovAliX Conference - Biophysics in Drug Discovery 2015

Confirmed Speakers


KEYNOTE LECTURE

Molecular Recognition in Protein-Ligand Complexes
Prof. Gerhard KLEBEProf. Gerhard KLEBE
(PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany)

Read more

INVITED LECTURES

SESSION 1: Method Development & Emerging Technologies

No Crystal, No Problem: Hydrogen Deuterium Exchange Mass Spectrometry in Drug Discovery
Dr Nino CAMPOBASSODr Nino CAMPOBASSO
(GLAXOSMITHKLINE, Collegeville, United States)

Read more
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Dr Pär NORDLUNDDr Pär NORDLUND
(KAROLINSKA INSTITUTE & NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore)

Read more
Second-Harmonic Generation (SHG) Measures and Resolves Protein Conformations: High-Throughput Structural Drug Discovery
Dr Joshua SALAFSKYDr Joshua SALAFSKY
(BIODESY, South San Francisco, United States)

Read more

SESSION 2: Biophysics for Integral Membrane Proteins

Fluorine NMR Screening: Principles and Application to a Membrane Protein
Dr Claudio DALVITDr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

Read more
Improving the Biophysical Properties of GPCRs for Drug Screening and Structural Biology
Prof. Andreas PLÜCKTHUNProf. Andreas PLÜCKTHUN
(UNIVERSITY OF ZÜRICH, Zurich, Switzerland)

Read more

SESSION 3: Impact of Biophysics on Drug Discovery Projects

Biophysical Approaches for Hit Finding and Evaluation at Bayer
Dr Ursula EGNERDr Ursula EGNER
(BAYER HEALTHCARE, Berlin, Germany)

Read more
Making Every Interaction Count: Impact of Biophysical Methods Across the AstraZeneca Small-Molecule Portfolio
Dr Stefan GESCHWINDNERDr Stefan GESCHWINDNER
(ASTRAZENECA, Mölndal, Sweden)

Read more
Some Examples of Biophysics Helping Drug Discovery
Prof. Rod HUBBARDProf. Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)

Read more
Biophysics and Structural Biology Enabling the Discovery of Therapeutic Solutions: from Small Molecule Inhibitors to Vaccine Design
Dr Vincent MIKOLDr Vincent MIKOL
(SANOFI, Vitry-sur-Seine, France)

Read more

SESSION 4: The Use of Kinetics in Drug Discovery

CCR2 Antagonists: From Structure-Kinetics Relatiosnhips to in vivo Efficacy
Dr Laura HEITMANDr Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

Read more
Towards a Better Understanding of the Structural Mechanisms of Kinase Inhibitor Binding Kinetics
Prof. Stefan KNAPPProf. Stefan KNAPP
(OXFORD UNIVERSITY, Oxford, United Kingdom)

Read more
Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure
Dr Herbert NARDr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)

Read more

SESSION 5: Special Focus on Epigenetics

When to get Biophysical with Readers, Writers and Erasers
Dr Chun-wa CHUNGDr Chun-wa CHUNG
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

Read more
Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics
Dr Robert A. COPELANDDr Robert A. COPELAND
(EPIZYME, Cambridge, United States)

Read more
Interrogating the Bromodomain Family Through Chemical Biology
Dr Richard CUMMINGSDr Richard CUMMINGS
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Read more

ORAL COMMUNICATIONS

Characterization of IL17A Inhibitors by Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS)
Mr Alfonso ESPADAMr Alfonso ESPADA
(ELI LILLY, MADRID, Spain)

Read more
A Universal Homogeneous Assay for High-Throughput Determination of Binding Kinetics
Dr Amaury Ernesto FERNANDEZ MONTALVANDr Amaury Ernesto FERNANDEZ MONTALVAN
(BAYER, Berlin, Germany)

Read more
Drug Discovery at the Single Molecule Level
Dr Anders GUNNARSSONDr Anders GUNNARSSON
(ASTRAZENECA, Mölndal, Sweden)

Read more
First Crystal Structure of Transmembrane Domain of G-Protein-Coupled Receptor MGLU5 Provides Insight Into Efficient New Drugs Design
Dr Krzysztof OKRASADr Krzysztof OKRASA
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

Read more
CDK8 Inhibitors with Long Residence Time Emerging from a Retro-Design Approach: New Opportunities for Cancer Treatment
Dr Anita WEGERTDr Anita WEGERT
(MERCACHEM, Nijmegen, The Netherlands)

Read more
Strategies to Target Protein-Protein Interactions
Dr Marta WESTWOODDr Marta WESTWOOD
(UCB, Slough, United Kingdom)

Read more

Organised by

Sponsors

Welcome Reception Sponsor

Media Partners

Copyright 2017 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys